- ISIN
- US02262M3088
- CUSIP
- 02262M308
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 15, 2021
Highlights
- Market Cap
- $5.10M
- Enterprise Value
- $4.39M
- EPS (TTM)
- -$1.96
- EBITDA (TTM)
- -$6.94M
- Year Range
- $0.84 - $2.68
- ROA (TTM)
- -338.66%
- ROE (TTM)
- -960.42%
- Avg. Volume (1M)
- 55K
- Avg. Volume Value (1M)
- $67.44K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALZN Performance Chart
Alzamend Neuro, Inc. (ALZN) is down 26.4% since the beginning of the year. At $1 per share, ALZN is trading 50.0% below its 52-week high of $3. Investors who bought $1,000 worth of ALZN shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Alzamend Neuro, Inc. (ALZN) has returned -26.37% so far this year and -39.09% over the past 12 months.
Alzamend Neuro, Inc.
- 1D
- 2.29%
- 1M
- 15.52%
- 6M
- -38.25%
- YTD
- -26.37%
- 1Y
- -39.09%
- 3Y*
- -86.60%
- 5Y*
- -81.31%
- 10Y*
- —
- ALL TIME*
- -86.51%
Benchmark (S&P 500 Index)
- 1D
- 1.48%
- 1M
- 1.57%
- 6M
- 8.95%
- YTD
- 11.03%
- 1Y
- 21.84%
- 3Y*
- 19.28%
- 5Y*
- 11.54%
- 10Y*
- 13.29%
- ALL TIME*
- 8.11%
ALZN Monthly Returns History
Based on dividend-adjusted daily data since Jun 15, 2021, ALZN's average daily return is -0.53%, while the average monthly return is -12.25%.
Historically, 30% of months were positive and 70% were negative. The best month was May 2023 with a return of +32.7%, while the worst month was Jun 2021 at -69.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 11 months.
On a daily basis, ALZN closed higher 42% of trading days. The best single day was Aug 19, 2024 with a return of +186.8%, while the worst single day was Jun 15, 2021 at -53.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.13% | -6.51% | -47.26% | 7.55% | 4.39% | 0.84% | 9.17% | 2.29% | -26.37% | ||||
| 2025 | -2.16% | -27.75% | 15.65% | -30.40% | -35.52% | -24.02% | -22.68% | 8.44% | -2.46% | 6.30% | -13.44% | -16.89% | -82.57% |
| 2024 | -3.37% | 6.52% | 9.16% | -28.90% | -17.02% | -33.15% | -9.48% | -34.17% | -28.09% | -7.10% | -17.20% | -10.77% | -86.97% |
| 2023 | 17.49% | -19.11% | -20.84% | 28.78% | 32.69% | -29.77% | -11.18% | -42.12% | -9.61% | -50.75% | -30.89% | -26.45% | -89.50% |
| 2022 | -19.47% | -22.88% | 4.24% | -17.07% | -7.70% | -8.19% | 2.86% | 1.79% | 31.49% | -1.68% | -1.71% | -50.88% | -70.27% |
| 2021 | -69.86% | -49.37% | -30.85% | 0.65% | -30.52% | -0.00% | -11.21% | -93.45% |
Benchmark Metrics
Alzamend Neuro, Inc. has an annualized alpha of -77.38%, beta of 1.07, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since June 15, 2021.
- This stock participated in 254.12% of S&P 500 Index downside but only -146.42% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -77.38%
- Beta
- 1.07
- R²
- 0.02
- Upside Capture
- -146.42%
- Downside Capture
- 254.12%
Return for Risk
Risk / Return Rank
ALZN ranks 21 for risk / return — above 21% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Alzamend Neuro, Inc. (ALZN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALZN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.23 | ||
| Sortino ratioReturn per unit of downside risk | -2.72 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.31 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | -0.58 | 2.41 | -2.99 |
| Martin ratioReturn relative to average drawdown | -1.08 | 10.22 | -11.31 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alzamend Neuro, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alzamend Neuro, Inc. was 100.00%, occurring on Apr 10, 2026. The portfolio has not yet recovered.
The current Alzamend Neuro, Inc. drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Apr 2026 | 4y 10mo | — | 5y 1moJun 2021 - now | — |
Drawdown Indicators
| ALZN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -67.27% | -9.10% | -58.17% |
Max Drawdown (3Y)Largest decline over 3 years | -99.85% | -18.90% | -80.95% |
Max Drawdown (5Y)Largest decline over 5 years | -99.98% | -25.43% | -74.55% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -0.12% | -99.88% |
Average DrawdownAverage peak-to-trough decline | -97.57% | -10.70% | -86.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 36.12% | 2.14% | +33.98% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alzamend Neuro, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alzamend Neuro, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALZN
Add Alzamend Neuro, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALZN